Valuation: EnteroMedics Inc

Market Cap 1.34Cr 1.19Cr 1.11Cr 1.01Cr 1.91Cr 128.87Cr 1.93Cr 13Cr 5.21Cr 66Cr 5.03Cr 4.92Cr 211.43Cr P/E 2026 *
-3.5x
P/E 2027 * -2.39x
Enterprise Value 1.34Cr 1.19Cr 1.11Cr 1.01Cr 1.91Cr 128.87Cr 1.93Cr 13Cr 5.21Cr 66Cr 5.03Cr 4.92Cr 211.43Cr EV / Sales 2026 *
122x
EV / Sales 2027 * 67x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 1L 97.29T 90.81T 82.77T 2L 1.05Cr 2L 10.99L 4L 53.81L 4L 4L 1.73Cr 2L 2L 2L 2L 3L 1.92Cr 3L 20.07L 8L 98.29L 8L 7L 3.15Cr
Net income -38L -33.76L -31.51L -28.72L -54.17L -37Cr -54.67L -3.81Cr -1.48Cr -19Cr -1.43Cr -1.4Cr -60Cr -78.46L -69.71L -65.06L -59.3L -1.12Cr -75Cr -1.13Cr -7.87Cr -3.05Cr -39Cr -2.95Cr -2.88Cr -123.75Cr
Net Debt - -
Logo EnteroMedics Inc
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-